Influence of Brazilian herbal regulations on the use and conservation of native medicinal plants

For decades, several native medicinal species have been used by the pharmaceutical industry in Brazil to create commercial products. In 1995, the Ministry of Health, following the recommendations of the World Health Organization, established herbal regulations (RDC 17) in order to improve the quality of such products. In fact, only plant species with conclusive results from pharmacological and toxicological studies can be used for creating medicines. In this study, we evaluated the consequences of RDC 17 on the use and conservation of native medicinal plants by comparing the plant material used by six companies in 1995/1996 and 10 years later (2005/2006). Eighty-three different species were used in 1995/1996, 50 of them native (60.2%), 16 exotic (19.3%), and 17 imported (20.5%). In 2005/2006, 44 species were used by the companies and only 19 (43.2%) were native. The category of plant material that saw the largest decrease in use was roots, and in 2005/2006 leaves were more used. The study shows a strong reduction in the collection of native species signalizing the importance of herbal regulations on their conservation. It also points to the need for pharmacological and toxicological studies of the Brazilian native medicinal flora, as well as studies on their ecology and conservation.